Skip to content, Open navigation eller Skip to contact information.

Copyright © Inderes 2011 - present. All rights reserved.
Latest
Börs
Aktiejämförelse
Kalender
Aktieanalys
Artiklar
inderesTV
Portfölj
Forum
About us
Våra kunder
Team
Settings
Copyright © Inderes 2011 - present. All rights reserved.

Latest content

Showing Alla typer av innehåll
Nexstim reported results on the use of accelerated iTBS protocol
Analytikerkommentar 2023-06-09 av Antti Siltanen
Nexstim
Nightingale announced new patent approvals
Analytikerkommentar 2023-05-24 av Antti Siltanen, Frans-Mikael Rostedt
Nightingale Health
Signs of recovery in the funding of biotechnology
Analytikerkommentar 2023-05-19 av Antti Siltanen
Aiforia TechnologiesFaron PharmaceuticalsNexstimBioretec
Nexstim received marketing authorization for its NBS6 product also in Europe
Analytikerkommentar 2023-05-19 av Antti Siltanen
Nexstim
Modulight: Start of the year was still difficult
Aktieanalys 2023-05-02 av Antti Siltanen
Modulight
Faron Pharmaceuticals: BEXMAB study’s good momentum supports valuation
Aktieanalys 2023-04-17 av Antti Siltanen
Faron Pharmaceuticals
Modulight: Towards profitable growth
Video 2023-03-27 av Antti Siltanen, Jeremias Makkonen
Modulight
According to FDA, bexmarilimab is safe, but dosage requires additional evidence
Analytikerkommentar 2023-03-23 av Antti Siltanen
Faron Pharmaceuticals
Nexstim’s guidance indicates profitability turnaround but industry companies seem to continue making losses
Analytikerkommentar 2023-03-21 av Antti Siltanen
Nexstim
Modulight: Laser company being calibrated towards growth
Omfattande aktieanalys 2023-03-20 av Antti Siltanen
Modulight